Overview
- Gilead will pay $115 per share in cash plus a $5 contingent value right tied to at least $6 billion in cumulative anito‑cel sales through 2029, valuing the deal at up to $7.8 billion.
- The companies expect the transaction to close in the second quarter of 2026, subject to customary approvals.
- Anito‑cel, a BCMA‑directed CAR‑T for relapsed or refractory multiple myeloma, is under FDA review as a fourth‑line therapy with a December 23, 2026 decision date.
- The acquisition converts Kite’s co‑development partnership into full ownership and brings Arcellx’s D‑Domain CAR platform that Gilead cites for next‑generation and potential in vivo cell‑therapy programs.
- Gilead already owns about 11.5% of Arcellx, projects EPS accretion starting in 2028 if anito‑cel is approved, and shares moved with Arcellx up roughly 78% as Gilead slipped about 1%.